Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Change in Accured Expenses (2019 - 2025)

Historic Change in Accured Expenses for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to $26.4 million.

  • BridgeBio Pharma's Change in Accured Expenses rose 139609.29% to $26.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $76.6 million, marking a year-over-year increase of 133337.07%. This contributed to the annual value of $17.0 million for FY2024, which is 11771.34% up from last year.
  • As of Q3 2025, BridgeBio Pharma's Change in Accured Expenses stood at $26.4 million, which was up 139609.29% from $46.0 million recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's Change in Accured Expenses ranged from a high of $46.0 million in Q2 2025 and a low of -$19.4 million during Q1 2025
  • For the 5-year period, BridgeBio Pharma's Change in Accured Expenses averaged around $4.4 million, with its median value being $4.5 million (2021).
  • As far as peak fluctuations go, BridgeBio Pharma's Change in Accured Expenses plummeted by 9308.81% in 2022, and later skyrocketed by 236964.29% in 2023.
  • Over the past 5 years, BridgeBio Pharma's Change in Accured Expenses (Quarter) stood at $18.6 million in 2021, then crashed by 92.51% to $1.4 million in 2022, then skyrocketed by 758.44% to $12.0 million in 2023, then skyrocketed by 97.34% to $23.6 million in 2024, then increased by 11.96% to $26.4 million in 2025.
  • Its last three reported values are $26.4 million in Q3 2025, $46.0 million for Q2 2025, and -$19.4 million during Q1 2025.